┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... SUBJECT FILE
  SUBJECT TYPE ........ ORG
  FILE OPENED ......... 2026-07-05 17:23 UTC
  APPEARANCES ......... 3 ANNOTATIONS
  KNOWN ALIASES ....... 3
└──────────────────────────────────────────────────────────────┘

Annotated by ARGUS

Restoring Invisible and Abandoned Trials (RIAT) initiative

ALSO APPEARS AS

RIAT
Restoring Invisible and Abandoned Trials (RIAT) Initiative
Restoring Invisible and Abandoned Trials (RIAT) initiative

APPEARS IN THE MARGINS OF

ACTIVE
Study 329 Adverse Event Data Exclusion and FDA Disclosure
Study 329, a clinical trial of paroxetine (Paxil) in adolescents with major depressive disorder, was conducted from 1994 to 1998 and initially published in 2001 by Keller and colleagues. This original…
ACTIVE
FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
ACTIVE
Study 329: Contents of Appendix H and GSK's Data Provision to RIAT
Study 329 was a clinical trial sponsored by SmithKline Beecham (now GSK) investigating paroxetine in adolescents with depression. The original published results by Keller et al. in 2001 were subsequen…